BIOMEDICAL

Chengdu Shibeikang Biomedical Technology Co., Ltd., established in 2015, is a national high-tech enterprise with a registered capital of 11.5596 million yuan. It is a new type of pharmaceutical company that integrates drug research and development and sales, rooted in China while facing the world. The company focuses on the research, development, and industrialization of innovative drugs for rare diseases and clinical urgent needs globally. Its current R&D pipeline includes multiple innovative drugs for rare diseases and clinical urgent needs, such as treatments for gastrointestinal stromal tumors after drug resistance, advanced systemic mastocytosis, multiple sclerosis, rare drug-resistant fungal infections, and stroke. These products are at various preclinical research stages and are gradually entering clinical trials.